At AMCP 2026, Kelsea Aragon, PharmD, discussed PrEP coverage, long-acting injectables, and payer strategies to improve HIV treatment access and adherence.
Kelsea Aragon, PharmD
Advertisement
Kelsea Aragon, PharmD, PhC, is an associate professor of pharmacy practice at the University of New Mexico College of Pharmacy.
Articles by Kelsea Aragon, PharmD
Kelsea Aragon, PharmD, highlights the role of long-acting HIV therapies like lenacapavir and cabotegravir in improving adherence, flexibility, and prevention access.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care
5